APA (7th ed.) Citation

A, G., V, P., M, L., MC, D. G., C, C., S, L., . . . J, T. (2026). Switch from cetuximab to panitumumab during encorafenib-based therapy in BRAF V600E mutated metastatic colorectal cancer: An international multicenter analysis from the AGEO group. Clinics and research in hepatology and gastroenterology, 50(1), 102746. https://doi.org/10.1016/j.clinre.2025.102746

Chicago Style (17th ed.) Citation

A, Gandini, et al. "Switch from Cetuximab to Panitumumab During Encorafenib-based Therapy in BRAF V600E Mutated Metastatic Colorectal Cancer: An International Multicenter Analysis from the AGEO Group." Clinics and Research in Hepatology and Gastroenterology 50, no. 1 (2026): 102746. https://doi.org/10.1016/j.clinre.2025.102746.

MLA (9th ed.) Citation

A, Gandini, et al. "Switch from Cetuximab to Panitumumab During Encorafenib-based Therapy in BRAF V600E Mutated Metastatic Colorectal Cancer: An International Multicenter Analysis from the AGEO Group." Clinics and Research in Hepatology and Gastroenterology, vol. 50, no. 1, 2026, p. 102746, https://doi.org/10.1016/j.clinre.2025.102746.